Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab plus CAPOX in advanced gastric/GEJ cancer
NCT03802591Phase 3Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of sugemalimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by CStone Pharmaceuticals. Started Mar 2019; status: completed.
02
Drugs
sugemalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03802591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802591.